^
Association details:
| Biomarker: | MET amplification |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug Class: | Immunotherapy |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Biomarkers to predict the efficacy of immune checkpoint inhibitors in patients with non-small-cell lung cancer with actionable genetic alterations.
Published date:
05/25/2023
Excerpt:
We compared the progression-free survival (PFS) of 324 advanced NSCLC patients who received ICI monotherapy (as over second-line therapy) by different AGAs....A total of 324 patients were included with the following AGAs: EGFR mutation (n = 149, 46.0%), ALK rearrangement, (n = 12, 3.7%), KRAS mutation (n = 72, 22.2%), HER2 mutation or amplification (n = 34, 10.5%), and MET ex14 skipping or amplification (n = 32, 9.9%), ROS1 rearrangement (n = 9, 2.8%), BRAF V600E (n = 9, 2.8%), and RET rearrangement (n = 7, 2.2%).....The 6-month PFS rate was 25.8% (19.5–34.3) in the group with KRAS/BRAF V600E/MET/HER2 and 12.8% (8.6–19.1) in the group with EGFR/ALK/ROS1/RET (P < 0.01)...the KRAS/BRAF V600E/MET/HER2 group had a favorable PFS compared with the EGFR/ALK/ROS1/RET group.
DOI:
10.1200/JCO.2023.41.16_suppl.e21175
Source:
Title:
First-Line Osimertinib in Patients With EGFR-Mutated Non-Small Cell Lung Cancer: Effectiveness, Resistance Mechanisms, and Prognosis of Different Subsequent Treatments
Published date:
11/11/2022
Excerpt:
Between January 1, 2016 and October 31, 2020, a consecutive of 56 EGFR-mutant lung cancer patients treated with osimertinib as first-line therapy at Daping Hospital (Chongqing, China) were retrospective screened....7 patients with EGFR C797 S or/and MET amplification received subsequent second-line targeted therapy, achieving mPFS of 7.3 months (95% CI 4.5 months -NA). Of note, 3 patients received immunotherapy as second- or third-line treatment after osimertinib resistance, achieving median clinical benefit of 37.3 months.
DOI:
10.1177/11795549221134735
Source:
Title:
P14.12 - MET Amplification and Immune Checkpoint Inhibitor Efficacy in NSCLC
Published date:
01/12/2021
Excerpt:
MET amplification was strongly associated with longer PFS times and with known immunotherapeutic response markers, including the TMB, the neoantigen load, immune-related genes, and high infiltration of specific immune cells, suggesting that MET amplification can be used as a novel predictive biomarker in NSCLC immunotherapy.
Source:
Title:
Genetic Heterogeneity of MET-aberrant Non-Small Cell Lung Cancer and its Impact on the Outcome of Immunotherapy
Published date:
12/09/2020
Excerpt:
In the MET-amplified NSCLC OS with ICI therapy was significantly better compared to chemotherapy with 19.0 months (95% CI: 15.8-22.2) vs. 8.0 months (95% CI: 5.8-10.2; p<0.0001).
DOI:
10.1016/j.jtho.2020.11.017
Source:
Title:
399P - Real-world insights into patients (pts) with advanced NSCLC and MET alterations
Published date:
11/17/2020
Excerpt:
Common treatments (METex14 vs METamp) were platinum-based therapy (1st line [1L], 44 vs 41%; 2nd line [2L], 35 vs 30%) and MET inhibitor monotherapy (1L, 33 vs 29%; 2L, 30 vs 39%). Immune checkpoint inhibitors (±chemotherapy) were used across 1L (13 vs 16%) and 2L (35 vs 13%). Median (95% CI) overall survival from start of 1L therapy (any) was 12.0 months (6.8, 19.2) in METex14 and 22.0 months (9.8, 31.2) in the METamp cohort.
Secondary therapy:
Chemotherapy
Source:
Title:
Effect of mesenchymal-epithelial transition amplification on immune microenvironment and efficacy of immune checkpoint inhibitors in patients with non-small cell lung cancer
Excerpt:
In the immunotherapy cohorts, MET amplification was associated with longer progression-free survival (PFS) times in patients receiving ICI treatment (P=0.039; HR =0.37; 95% CI: 0.18-0.73).
DOI:
10.21037/atm-21-4543
